Copyright: ©Author(s) 2026.
World J Hepatol. Mar 27, 2026; 18(3): 115411
Published online Mar 27, 2026. doi: 10.4254/wjh.v18.i3.115411
Published online Mar 27, 2026. doi: 10.4254/wjh.v18.i3.115411
Figure 4 Forest plot of outcomes.
A: Serious adverse events; B: Adverse events leading to discontinuation; C: Nausea; D: Diarrhea; E: Injection site reaction. CI: Confidence interval.
- Citation: Alam U, Rath S, Ansab M, Kashif A, Sethi FA, Siddiqui HT, Afridi ZAK, Burhan M, Ali MA, Moiz A, Bacha Z, Khan A, Ahmed R, Alatise MB, Kamil KA. Efruxifermin in patients with metabolic dysfunction-associated steatohepatitis: A GRADE-assessed systematic review and meta-analysis. World J Hepatol 2026; 18(3): 115411
- URL: https://www.wjgnet.com/1948-5182/full/v18/i3/115411.htm
- DOI: https://dx.doi.org/10.4254/wjh.v18.i3.115411